Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-03-22
2011-03-22
Ford, Vanessa L. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S184100
Reexamination Certificate
active
07910116
ABSTRACT:
Methods for treating gastric disorders, such as GERD and delayed gastric emptying, by intramuscular administration of abotulinumtoxin to a head, neck and/or shoulder muscle of a patient with a gastric disorder.
REFERENCES:
patent: 5427291 (1995-06-01), Smith
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5714468 (1998-02-01), Binder
patent: 5756468 (1998-05-01), Johnson et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6358917 (2002-03-01), Carruthers et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6623742 (2003-09-01), Voet
patent: 6787517 (2004-09-01), Gil et al.
patent: 6838434 (2005-01-01), Voet
patent: 2004/0037865 (2004-02-01), Miller
patent: 2004/0086531 (2004-05-01), Barron
patent: 2005/0147626 (2005-07-01), Blumenfeld
patent: 2006/0083758 (2006-04-01), Dadas
patent: 0 605 501 (1994-07-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO2004/041303 (2004-05-01), None
Gui (Arch Pharmacol Jun. 2002, 365(Suppl 2):R22)).
Thumshirn et al (Schweiz Rundsch Med Prax., Oct. 16, 2002;91(42):1741-7) (Abstract only).
(Cephalagia, 2002, 22, 555-556).
Friedenberg et al (Digestive Diseases and Sciences , vol., No. 2 Feb. 2004).
Ahuja et al (American Family Physician, vol. 60, No. 3, Sep. 1, 1999).
Spierings et al (Cephalalgia, 2002, 22, p. 555-556).
Khawaja (International Journal of Dermatology 2001, 40, 311-317).
Qureshi (Journal of Clincial Gastroenterol, 200;34(2):126-128).
Friedenberg et al (Digestive Diseases and Sciences , vol. 49, No. 2 Feb. 2004).
Keir, James,Botulinum Toxin—Physiology and Applications in Head and Neck Disorders, Neck & Head, Jun. 2005, pp. 525-535.
Lacy, Brian E., et al.,The Treatment of Diabetic Gastroparesis with Botulinum Toxin Injection of the Pylorus, Diabetes Care, vol. 27, No. 10, Oct. 2004, pp. 2341-2347.
Miller, Larry S., et al.,Treatment of Idiopathic Gastroparesis with Injection of Botulinum Toxin into the Pyloric Sphincter Muscle, The American Journal of Gastroenterology, vol. 97, No. 7, 2002, pp. 1653-1660.
Zhao, Xiaotuan, et al.,Botulinum Toxin for Spastic GI Disorders: A Systematic Review, Gastrointestinal Endoscopy, vol. 57, No. 2, 2003, pp. 219-235.
Albanese A., et al.,The use of botulinum toxin on smooth muscles, Eur J Neurol Nov. 1995; 2(Supp 3):29-33.
Bigalke H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360; 318-324:1985.
Bigalke H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981.
Binz T. et al.,The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins, J Biological Chemistry 265(16);9153-9158:1990.
Boyd R.S. et al.,The effect of botulinum neurotoxin-B on insulin release from a β- cell line, Mov Disord, 10(3):376:1995, Abstract 19.
Boyd R.S. et al.,The insulin secreting β-cell line, HIT-15, contains SNAP-25 which is a target for botulinum neurotoxin-A, Mov Disord, 10(3):376-1995, Abstract 20.
Dykstra, D.D., et al,Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study, Arch Phys Med Rehabil Jan. 1990; 71:24-6.
Eaker, E.Y., et al.,Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia, Dig Dis Sci Apr. 1997;42(4):724-7.
Gonelle-Gispert, C., et al.,SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion, Biochem J. 1;339 (pt 1):159-65:1999.
Gui D., et al.,Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats, Aliment Pharmacol Ther Jun. 2000;14(6):829-834.
Gui D., et al.,Effects of botulinum toxin on gastric emptying and digestive secretions. A possible tool for correction of obesity?,Naunyn Schmiedebergs Arch Pharmacol Jun. 2002;365(Suppl 2):R22.
Habermann E., et al.,Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2);522-527:1988.
Habermann E,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia 44;224-226:1988.
Habermann, (125I-labelled Neurotoxin from clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord, Naunyn-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14thedition, published by McGraw Hill.
Coffield, Eds. Jankovic J. et al.,Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), Chapter 1.
Kohl A., et al., Comparison of the effect of botulinum toxin A (Botox (R)) with the highly-purified neurotoxin (NT 201) in the extensor digitorum brevis muscle test, Mov Disord 2000; 15(Suppl3):165.
Kondo T., et al.,Modification of the action of pentagastrin on acid secretion by botulinum toxin, Experientia 1977;33:750-1.
Marjama-Lyons, J., et al.,Tremor-Predominant Parkinson's Disease, Drugs & Aging 16(4);273-278:2000.
Meyer K.E. et al,A Comparative Systemic Toxicity Study of Neurobloc in Adult Juvenile Cynomolgus Monkeys, Mov. Disord 15(Suppl 2);54;2000.
Moyer E et al.,Botulinum Toxin Type B: Experimental and Clinical Experience, chapter 6, pp. 71-85 of “Therapy With Botulinum Toxin”, edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
Naumann M., et al.,Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European J. Neurology 6 (Supp 4):S111-S115:1999.
Sloop,Neurology, 48:249-53:1997.
Pearce, L.B.,Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine, Toxicon 35(9);1373-1412 at 1393, 1997.
Ragona, R.M., et al.,Management of partoid sialocele with botulinum toxin, The Laryngoscope 109:1344-1346:1999.
Rohrbach S., et al.,Botulinum toxin type A induces apoptosis in nasaal glands of guinea pigs, Ann Otol Rhinol Laryngol Nov. 2001;110(11):1045-50.
Rohrbach S., et al.,Minimally invasive application of botulinum toxin type A in nasal hypersecretion, J Oto-Rhino-Laryngol Nov.-Dec. 2001;63(6):382-4.
Rossi S., et al.,Immunohistochemical localization of SNAP-25 protein in the stomach of rat, Naunyn Schmiedebergs Arch Pharmacol 2002;365(Suppl 2):R37.
Sanchez-Prieto, J., et al.,Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes, Eur J. Biochem 165;675-681:1987.
Schantz E.J., et al Preparation and characterization of botulinum toxin type A for human treatment (in particular pp. 44-45), chapter 3 of Jankovic, J., et al, Therapy with Botulinum Toxin, Marcel Dekker, Inc (1994).
Schantz, E.J., et al,Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine, Microbiol Rev. 56;80-99:1992.
Singh,Critical Aspects of Bacterial Protein Toxins, pp. 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1996).
Wang Z., et al.,Effects of botulinum toxin on gastric myoelectrical and vagal activities in dogs, Gastroenterology Apr. 2001;120(5 Suppl 1):A-718.
Weigand et al, (125I-labelled botulinum A neurotoxin:pharmacokinetics in cats after intramuscular injection, Nauny-Schmiedeberg's Arch. Pharmacol. 1976;292, 161-165.
Wiesel P.H. et al.,Botulinum toxin
Abel Kenton
Allergan Inc.
Condino Debra
Ford Vanessa L.
LandOfFree
Use of a botulinum toxin to improve gastric emptying and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a botulinum toxin to improve gastric emptying and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a botulinum toxin to improve gastric emptying and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2782496